Literature DB >> 19455281

Atrial septal defect closure and migraine with aura: is there a correlation?

Paola Castellini1, Giorgio Lambru, Gian Camillo Manzoni, Paola Torelli.   

Abstract

Recently, some authors detected increased frequency or new onset of migraine with aura (MA) after atrial septal defect (ASD) closure. We report the effects of ASD closure on the occurrence of MA in three patients of Parma Headache Centre. Two of them developed MA after the procedure one had a worsening of pre-existing MA. The increased frequency or the de novo onset of MA after ASD closure may be related to the alteration of some physiological variables that play a central role in the physiopathogenetic mechanisms of MA and may trigger attacks in predisposed individuals. In previous literature reports, the new pattern of MA appeared self-limiting within a few weeks or months. In our cases, it seemed to last longer, but the natural history of this headache subtype suggests that this finding could be related to the extended duration of our follow-up and to the prospective nature of our study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455281     DOI: 10.1007/s10072-009-0094-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  16 in total

1.  Closure of atrial septal defect and migraine.

Authors:  Vinod Kumar Gupta
Journal:  Headache       Date:  2004-03       Impact factor: 5.887

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  Intense migraines secondary to percutaneous closure of atrial septal defects.

Authors:  Mohsen Sharifi; Majid Dehghani; Mahshid Mehdipour; Omar Al-Bustami; Farnaz Emrani; James Burks
Journal:  J Interv Cardiol       Date:  2005-06       Impact factor: 2.279

4.  Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study.

Authors:  G P Anzola; M Magoni; M Guindani; L Rozzini; G Dalla Volta
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

Review 5.  [Autonomic nervous activity in migraine].

Authors:  N Araki
Journal:  Rinsho Shinkeigaku       Date:  1995-12

6.  The influence of percutaneous atrial septal defect closure on the occurrence of migraine.

Authors:  Katrin Mortelmans; Martijn Post; Vincent Thijs; Luc Herroelen; Werner Budts
Journal:  Eur Heart J       Date:  2005-03-03       Impact factor: 29.983

7.  Platelet aggregation and atrial natriuretic peptide.

Authors:  S Ulker; S Akgür; A Evinç; N Soykan; S Koşay
Journal:  Gen Pharmacol       Date:  1995-10

8.  Migraine symptoms related to the percutaneous closure of an ostium secundum atrial septal defect: report of four paediatric cases and review of the literature.

Authors:  D M Fernández-Mayoralas; A Fernández-Jaén; N Muñoz-Jareño; F Gutiérrez-Larraya; B Calleja-Pérez; V San Antonio Arce
Journal:  Cephalalgia       Date:  2007-04-25       Impact factor: 6.292

9.  Transformation into daily migraine with aura following transcutaneous atrial septal defect closure.

Authors:  A E Yankovsky; A Kuritzky
Journal:  Headache       Date:  2003-05       Impact factor: 5.887

10.  Migraine with aura related to the percutaneous closure of an atrial septal defect.

Authors:  Josep Rodés-Cabau; Carlos Molina; Carmen Serrano-Munuera; Jaume Casaldáliga; José Alvarez-Sabin; Arturo Evangelista; Jordi Soler-Soler
Journal:  Catheter Cardiovasc Interv       Date:  2003-12       Impact factor: 2.692

View more
  2 in total

1.  Migraine headaches following catheter ablation for atrial fibrillation.

Authors:  Amit Noheria; John Roshan; Suraj Kapa; Komandoor Srivathsan; Douglas L Packer; Samuel J Asirvatham
Journal:  J Interv Card Electrophysiol       Date:  2010-10-19       Impact factor: 1.900

Review 2.  Migraine Modulation and Debut after Percutaneous Atrial Septal Defect Closure: A Review.

Authors:  Charles Stevens Leger; Joseph F X DeSouza
Journal:  Front Neurol       Date:  2017-03-20       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.